These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 12568499

  • 21. Effect of tiotropium on mucus hypersecretion and airway clearance in patients with COPD.
    Tagaya E, Yagi O, Sato A, Arimura K, Takeyama K, Kondo M, Tamaoki J.
    Pulm Pharmacol Ther; 2016 Aug; 39():81-4. PubMed ID: 27350218
    [Abstract] [Full Text] [Related]

  • 22. Rationale of airway clearance.
    Clarke SW.
    Eur Respir J Suppl; 1989 Jul; 7():599s-603s. PubMed ID: 2679608
    [Abstract] [Full Text] [Related]

  • 23. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J, Puech A, Boissel JP, Participants inRound Table No 7, Giens XXII.
    Therapie; 2007 Jul; 62(5):427-35. PubMed ID: 18206104
    [Abstract] [Full Text] [Related]

  • 24. [Mucolytics in acute and chronic respiratory tract disorders. II. Uses for treatment and antioxidant properties].
    Kupczyk M, Kuna P.
    Pol Merkur Lekarski; 2002 Mar; 12(69):248-52. PubMed ID: 12053601
    [Abstract] [Full Text] [Related]

  • 25. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
    Sobieraj DM, White CM, Coleman CI.
    Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
    [Abstract] [Full Text] [Related]

  • 26. The airway pathophysiology of COPD: implications for treatment.
    Rodríguez-Roisin R.
    COPD; 2005 Jun; 2(2):253-62. PubMed ID: 17136952
    [Abstract] [Full Text] [Related]

  • 27. Plant-based formulation in the management of chronic obstructive pulmonary disease: a randomized double-blind study.
    Murali PM, Rajasekaran S, Paramesh P, Krishnarajasekar OR, Vasudevan S, Nalini K, Lakshmisubramanian S, Deivanayagam CN.
    Respir Med; 2006 Jan; 100(1):39-45. PubMed ID: 15905081
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Mucolytics in acute and chronic respiratory tract disorders. I. Pathophysiology and mechanisms of action].
    Kupczyk M, Kuna P.
    Pol Merkur Lekarski; 2002 Mar; 12(69):245-7. PubMed ID: 12053600
    [Abstract] [Full Text] [Related]

  • 30. Mucoactive drugs for asthma and COPD: any place in therapy?
    Rogers DF.
    Expert Opin Investig Drugs; 2002 Jan; 11(1):15-35. PubMed ID: 11772318
    [Abstract] [Full Text] [Related]

  • 31. A view on imaging in drug research and development for respiratory diseases.
    van Echteld CJ, Beckmann N.
    J Pharmacol Exp Ther; 2011 May; 337(2):335-49. PubMed ID: 21317353
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels.
    Willke RJ, Burke LB, Erickson P.
    Control Clin Trials; 2004 Dec; 25(6):535-52. PubMed ID: 15588741
    [Abstract] [Full Text] [Related]

  • 34. Evaluation of the activity of the carbocysteine-sobrerol combination on mucus spinnability.
    Distefano SM, Palermo F, Crimi N, Mistretta A, Pamparana F, Messa A.
    Int J Clin Pharmacol Res; 1988 Dec; 8(1):31-5. PubMed ID: 3284830
    [Abstract] [Full Text] [Related]

  • 35. Mucoactive drugs.
    Balsamo R, Lanata L, Egan CG.
    Eur Respir Rev; 2010 Jun; 19(116):127-33. PubMed ID: 20956181
    [Abstract] [Full Text] [Related]

  • 36. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data.
    Cazzola M, Floriani I, Page CP.
    Pulm Pharmacol Ther; 2010 Apr; 23(2):135-44. PubMed ID: 19854285
    [Abstract] [Full Text] [Related]

  • 37. Erdosteine for COPD exacerbations.
    Drug Ther Bull; 2008 Oct; 46(10):79-80. PubMed ID: 18832259
    [Abstract] [Full Text] [Related]

  • 38. Mucoactive medications and airway disease.
    Majima Y.
    Paediatr Respir Rev; 2002 Jun; 3(2):104-9. PubMed ID: 12297055
    [Abstract] [Full Text] [Related]

  • 39. Designing clinical trials to evaluate mucus clearance therapy.
    Rubin BK.
    Respir Care; 2007 Oct; 52(10):1348-58; discussion 1358-61. PubMed ID: 17894903
    [Abstract] [Full Text] [Related]

  • 40. Physiology of airway mucus clearance.
    Rubin BK.
    Respir Care; 2002 Jul; 47(7):761-8. PubMed ID: 12088546
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.